Newsroom | 73371 results

Sorted by: Latest
Science
-

Silvec Announces EPA Registration for its Novel Therapy Delivery Technology

GAITHERSBURG, Md.--(BUSINESS WIRE)--Silvec Biologics Inc., a Maryland-based agricultural biotechnology company, is pleased to announce that its novel RNA-based therapy delivery product is now registered for unconditional commercial use under the U.S. Environmental Protection Agency’s (EPA) Federal Insecticide, Fungicide and Rodenticide Act. The product is based on a naturally non-transmitted version of the citrus tristeza virus that is already found in most Florida citrus trees that has been re...
-

Anaergia Reports 98% Revenue Growth, Fourth Consecutive Quarter of Positive Adjusted EBITDA, and Revenue Backlog Expansion to $274.9 Million in Q2 2026

BURLINGTON, Ontario--(BUSINESS WIRE)--Anaergia (TSX: ANRG, OTCQX: ANRGF) Q2 2026: revenue up 98% to $63.9M, fourth consecutive quarter of positive Adjusted EBITDA, Revenue Backlog $274.9M....
-

BeOne Medicines وRevolution Medicines تعلنان عن شراكة للتطوير السريري والتسويق التجاري الإقليمي

سان كارلوس، كاليفورنيا و ريدوود سيتي، كاليفورنيا--(BUSINESS WIRE)--أعلنت BeOne Medicines Ltd. (المدرجة في بورصة ناسداك بالرمز: ONC؛ وبورصة هونج كونج: 06160؛ وبورصة شنغهاي: 688235)، إحدى الشركات العالمية المتخصصة في علم الأورام، وRevolution Medicines, Inc. (المدرجة في بورصة ناسداك بالرمز: RVMD)، وهي شركة متخصصة في تطوير علاجات موجهة للمرضى المصابين بالسرطانات المعتمدة على RAS وفي مرحلة متقدمة من التطوير السريري، عن إبرام تعاون متعدد الأوجه يتضمن محورين رئيسيين: تعاونًا سريريًا لتقييم تركيبات دوائ...
-

Amentum Reports Third Quarter Fiscal Year 2026 Results

CHANTILLY, Va.--(BUSINESS WIRE)--Amentum (NYSE: AMTM), a leading advanced engineering and technology company, today announced results for the third quarter ended July 3, 2026....
-

QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx BCID GPF Plus AMR Panel, the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance. The clearance expands QIAGEN’s U.S. syndromic testing portfolio into bloodstream infection diagnostics, the fourth major infectious disease area covered by the QIAstat-Dx platform, which is availa...
-

Feinstein Institutes Finds Mitochondria Transplantation Dramatically Enhances Heart Recovery After Cardiac Arrest

MANHASSET, N.Y.--(BUSINESS WIRE)--With only approximately 10 percent of out-of-hospital cardiac arrest patients surviving, and many facing severe neurological or organ damage, a new study from Northwell Health’s Feinstein Institutes for Medical Research offers hope, revealing that mitochondria transplantation dramatically improves heart recovery and protects organs. Published as a letter to the editor in the American Journal of Respiratory and Critical Care Medicine (AJRCCM), this pivotal large...
-

BeOne MedicinesとRevolution Medicines、臨床開発および地域別商業化に向けた提携を発表

米カリフォルニア州サンカルロスおよびカリフォルニア州レッドウッドシティ--(BUSINESS WIRE)--（ビジネスワイヤ） -- 腫瘍分野でグローバルに展開するBeOne Medicines（ナスダック：ONC、香港証券取引所：06160、上海証券取引所：688235、「BeOne」）とRAS依存性癌患者向けに後期臨床段階で腫瘍標的療法を開発するRevolution Medicines（ナスダック：RVMD）は、多岐にわたる提携を発表しました。この提携には、BeOneの特定の臨床段階にある腫瘍関連の薬剤資産と、Revolution Medicinesの4種類の臨床段階にあるRAS（ON）阻害剤との併用療法を評価する臨床提携、および特定のアジア市場におけるRevolution Medicinesの薬剤資産の独占的な開発・商業化権をBeOneに付与する地域別権利契約が含まれます。 この臨床提携は、RAS依存性癌患者を対象とした標的併用療法のアプローチの可能性を模索 臨床提携の一環として開発が検討される併用療法の候補には、BeOneの特定の薬剤候補と、Revolution Medici...
-

BeOne Medicines e Revolution Medicines anunciam cooperação para desenvolvimento clínico e comercialização regional

SAN CARLOS, Califórnia e REDWOOD CITY, Califórnia--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), uma empresa multinacional de oncologia, e Revolution Medicines, Inc. (Nasdaq: RVMD), Uma empresa de oncologia clínica em estágio avançado que desenvolve terapias direcionadas a pacientes com tipos de câncer que dependem de RAS anunciou hoje uma cooperação de múltiplas etapas, incluindo: uma cooperação clínica para avaliar combinações de medicamentos que incorporem at...
-

BeOne Medicines y Revolution Medicines anuncian una colaboración para el desarrollo clínico y la comercialización en determinados mercados asiáticos

SAN CARLOS, California, y REDWOOD CITY, California--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), una empresa global especializada en oncología, y Revolution Medicines, Inc. (Nasdaq: RVMD), una empresa biofarmacéutica en fase clínica avanzada que desarrolla terapias dirigidas para pacientes con cánceres dependientes de RAS, anunciaron hoy una colaboración que comprende dos acuerdos. El primero es una colaboración clínica para evaluar combinaciones de determinado...
-

Memphis Tradition of Hope Continues to Change Children's Lives During the 2026 FedEx St. Jude Championship Benefiting St. Jude Children's Research Hospital®

MEMPHIS, Tenn.--(BUSINESS WIRE)--As 70 of the world's best golfers descend on Memphis for the 2026 FedEx St. Jude Championship, patients from St. Jude Children’s Research Hospital® will once again be at the heart of tournament week, showcasing the powerful impact of the supporters, partners and communities helping advance its lifesaving mission. The 2026 FedEx St. Jude Championship, Aug. 13-16 at TPC Southwind, brings together the top players in the FedExCup standings while continuing a decades...